Effects of Sacubitril/Valsartan on Physical and Social Limitations in Patients With Heart Failure

Original Investigation  Research


CORRECTION

Error in Figure Data: In the Original Investigation titled “Long-term Thromboembolic Risk in Patients with Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients with Nonvalvular Atrial Fibrillation,” published online on March 28, 2018, there were errors in the hazard ratios and 95% CIs presented in Figure 3. The correct values for the odds of a thromboembolic event after oral anticoagulant therapy for patients with nonvalvular atrial fibrillation were 0.59 (95% CI, 0.51-0.68), for the odds of death after oral anticoagulant therapy for patients with postoperative atrial fibrillation, 1.09 (95% CI, 0.82-1.43), and for patients with nonvalvular atrial fibrillation, 0.51 (95% CI, 0.47-0.55).


Error in End Matter: The Original Investigation titled “Association of Methylations Signals With Incident Coronary Heart Disease in an Epigenome-Wide Assessment of Circulating Tumor Necrosis Factor α,” published online on April 4, 2018, omitted a list of multiple first and senior authors from the end matter. It should have noted that Drs Agha, Colicino, Do, Lahti, Ligthart, Marioni, Marzi, Mendelson, Tanaka, and Wielscher were first authors; Ms Baccarelli and Drs Bandinelli, Deary, Dehghan, Eriksson, Herder, Jarvelin, and Levy were senior authors; Dr Aslibekyan was overall first author; and Dr Arnett was overall senior author. The article has been corrected online.